

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
20 June 2002 (20.06.2002)

PCT

(10) International Publication Number
WO 02/47456 A2

(51) International Patent Classification: Not classified

(21) International Application Number: PCT/US01/46370

(22) International Filing Date: 5 December 2001 (05.12.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/254,594 11 December 2000 (11.12.2000) US

(71) Applicant (for all designated States except US):
SMITHKLINE BEECHAM CORPORATION
[US/US]; One Franklin Plaza, P.O. Box 7929, Philadelphia, PA 19103 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **DHANAK, Dashyant** [GB/US]; 709 Swedeland Road, King of Prussia, PA 19406 (US). **KNIGHT, Steven, D.** [US/US]; 709 Swedeland Road, King of Prussia, PA 19406 (US).

(74) Agents: **HALL, Linda, E.** et al.; SmithKline Beecham Corporation, Corporate Intellectual Property, UW2220, 709 Swedeland Road, P.O. Box 1539, King of Prussia, PA 19406-0939 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 02/47456 A2

(54) Title: UROTENSIN-II RECEPTOR ANTAGONISTS

(57) Abstract: The present invention relates to novel quinolones and their use as urotensin antagonists.

UROTENSIN-II RECEPTOR ANTAGONISTS

FIELD OF THE INVENTION

The present invention relates generally to novel quinolones, and their use as antagonists of urotensin II.

5

BACKGROUND OF THE INVENTION

The integrated control of cardiovascular homeostasis is achieved through a combination of both direct neuronal control and systemic neurohormonal activation. Although the resultant release of both contractile and relaxant factors is normally under stringent regulation, an aberration in this *status quo* can result in cardiohemodynamic dysfunction with pathological consequences.

The principal mammalian vasoactive factors that comprise this neurohumoral axis, namely angiotensin-II, endothelin-1, norepinephrine, all function via an interaction with specific G-protein coupled receptors (GPCR). Urotensin-II, represents a novel member of this neurohumoral axis.

In the fish, this peptide has significant hemodynamic and endocrine actions in diverse end-organ systems and tissues:

- smooth muscle contraction

both vascular and non-vascular in origin including smooth muscle preparations from the gastrointestinal tract and genitourinary tract. Both pressor and depressor activity has been described upon systemic administration of exogenous peptide

- osmoregulation:

effects which include the modulation of transepithelial ion (Na^+ , Cl^-) transport.

Although a diuretic effect has been described, such an effect is postulated to be secondary to direct renovascular effects (elevated GFR)

- metabolism:

urotensin-II influences prolactin secretion and exhibits a lipolytic effect in fish (activating triacylglycerol lipase resulting in the mobilization of non-esterified free fatty acids)

(Pearson, *et. al. Proc. Natl. Acad. Sci. (U.S.A.)* **1980**, 77, 5021; Conlon, *et. al. J. Exp. Zool.* **1996**, 275, 226.)

In studies with human Urotensin-II it was found that it:

- was an extremely potent and efficacious vasoconstrictor
- exhibited sustained contractile activity that was extremely resistant to wash out

- had detrimental effects on cardiac performance (myocardial contractility)

Human Urotensin-II was assessed for contractile activity in the rat-isolated aorta and was shown to be the most potent contractile agonist identified to date. Based on the *in vitro* pharmacology and *in vivo* hemodynamic profile of human Urotensin-II it plays a pathological
5 role in cardiovascular diseases characterized by excessive or abnormal vasoconstriction and myocardial dysfunction. (Ames *et. al. Nature* **1999**, *401*, 282)

Compounds that antagonize the Urotensin-II receptor may be useful in the treatment of congestive heart failure, stroke, ischemic heart disease (angina, myocardial ischemia), cardiac arrhythmia, hypertension (essential and pulmonary), COPD, restenosis, asthma, (Hay DWP,
10 Luttmann MA, Douglas SA: 2000, Br J Pharmacol: In press.) neurogenic inflammation and metabolic vasculopathies all of which are characterized by abnormal vasoconstriction and/or myocardial dysfunction. Since U-II and GPR14 are both expressed within the mammalian CNS (Ames *et. al. Nature* **1999**, *401*, 282), they also may be useful in the treatment of addiction, schizophrenia, impulsivity, anxiety, stress, depression, and neuromuscular function. Functional
15 U-II receptors are expressed in rhabdomyosarcomas cell lines and therefore may have oncological indications. Urotensin may also be implicated in various metabolic diseases such as diabetes (Ames *et. al. Nature* **1999**, *401*, 282, Nothacker et al., *Nature Cell Biology* 1: 383-385, 1999).

SUMMARY OF THE INVENTION

20 In one aspect this invention provides for quinolones and pharmaceutical compositions containing them.

In a second aspect, this invention provides for the use of quinolones as antagonists of urotensin II, and as inhibitors of urotensin II.

In another aspect, this invention provides for the use of quinolones for treating
25 conditions associated with urotensin II imbalance.


In an yet another aspect, this invention provides for the use of these quinolones analogs for the treatment of congestive heart failure, stroke, ischemic heart disease (angina, myocardial ischemia), cardiac arrhythmia, hypertension (essential and pulmonary), COPD, restenosis, asthma, neurogenic inflammation and metabolic vasculopathies, addiction, schizophrenia,
30 impulsivity, anxiety, stress, depression, neuromuscular function, and diabetes.

The urotensin antagonist may be administered alone or in conjunction with one or more other therapeutic agents, said agents being selected from the group consisting of endothelin receptor antagonists, angiotensin converting enzyme (ACE) inhibitors, vasopeptidase inhibitors, diuretics, digoxin, and dual non-selective β -adrenoceptor and α_1 -adrenoceptor
35 antagonists.

Other aspects and advantages of the present invention are described further in the following detailed description of the preferred embodiments thereof.

DETAILED DESCRIPTION OF THE INVENTION

5 The present invention provides for compounds of Formula I:



wherein:

- 10 R_1 is phenyl, thienyl, benzothienyl, benzhydryl, xanthenyl, naphthyl, or indolyl, all of which may be substituted or unsubstituted by one or two substituents selected from: halogens, -CN, $\text{CH}_3\text{CO}-$, (C_{1-6}) alkyl, mono to perfluoro (C_{1-3}) alkyl, (C_{2-6}) alkenyl, (C_{1-6}) alkoxy, (C_{5-10}) aryloxy, phenyl (C_{1-6}) alkoxy, -OH, - NH_2 , mono- or di- (C_{1-6}) alkylamino, - NO_2 , - CO_2H , - $\text{CO}_2(\text{C}_{1-6})$ alkyl, - $\text{S}(\text{C}_{1-6})$ alkyl, - $\text{SO}_2(\text{C}_{1-6})$ alkyl, H_2NSO_2- , -CONH $_2$,
 15 - $\text{SO}_2(\text{C}_{5-10})$ aryl, or - $\text{CO}_2\text{N}\{(\text{C}_{1-6})\text{alkyl}\}_2$;
 R_2 is hydrogen or Me;
 R_3 is hydrogen, I, F, Br, Cl, C_{1-6} alkyl, C_{1-6} alkoxy, -OH, or -CN;
 X is -CH(R_4)-;
 R_4 is hydrogen, CO, C_{1-6} alkyl, or phenyl;
 20 Y is -CH $_2\text{C}(\text{R}_5)(\text{R}_6)\text{CH}_2-$;
 R_5 is hydrogen, C_{1-6} alkyl, C_{3-6} cycloalkyl, benzyl, or phenyl, wherein the benzyl or phenyl group may be substituted or unsubstituted by one or two carboxy, cyano, OH or halo groups;
 R_6 is benzyl, C_{3-6} cycloalkyl, or phenyl, wherein the benzyl or phenyl group may be substituted or unsubstituted by one or two carboxy, cyano, OH or halo groups;
 25 or R_5 and R_6 together with the carbon they are attached to may form a C_{3-7} cycloalkyl group;
 or a pharmaceutically acceptable salt thereof.

When used herein, the term "alkyl" and similar terms such as "alkoxy" includes all straight chain and branched isomers. Representative examples thereof include methyl, ethyl, *n*-propyl, *iso*-propyl, *n*-butyl, *sec*-butyl, *iso*-butyl, *t*-butyl, *n*-pentyl and *n*-hexyl.

When used herein, the terms 'halogen' and 'halo' include fluorine, chlorine, bromine and
5 iodine and fluoro, chloro, bromo and iodo, respectively.

By the term "aryl" as used herein, unless otherwise defined, is meant cyclic or polycyclic aromatic C₅-C₁₂ ring. Examples are phenyl and naphthyl.

The compounds of the present invention may contain one or more asymmetric carbon atoms and may exist in racemic and optically active form. All of these compounds and their
10 diastereoisomers are contemplated to be within the scope of the present invention.

Preferably R₁ is substituted phenyl, thienyl, benzothienyl, benzhydryl, or indolyl. More preferably R₁ is 1-benzyl-3-indolyl, 4,6-dichloro-2-indolyl, 3-trifluoromethylthiophenyl, 2-fluoro-5-trifluoromethylphenyl, 4,6-dichloro-3-methyl-2-indolyl, 6-methoxy-4-trifluoromethyl-2-indolyl, or 3,4-dichlorophenyl, 3,5-dibromophenyl.

15 Preferably R₂ is hydrogen;

Preferably R₃ is hydrogen, halo, or alkyl; more preferably R₃ is hydrogen, Cl, or Me.

Preferably X is CH₂.

Preferably R₅ is

Preferably R₆ is


20 Preferred Compounds are:

2-{3-[(1-Benzyl-1*H*-indol-3-ylmethyl)-amino]-2-phenyl-propylamino}-1*H*-quinolin-4-one; and
2-[(1-[(1-Benzyl-1*H*-indol-3-ylmethyl)-amino]-methyl)-cyclohexylmethyl)-amino]-1*H*-quinolin-4-one.

Compounds of Formula (I) may be prepared as outlined in the following scheme:

25


Scheme 1



Conditions: a) Dimethylsulfate, methylene chloride, acetone, reflux; b) trifluoroacetic anhydride, pyridine, rt; c) Di-*tert*-butyl dicarbamate, tetrahydrofuran, rt; d) **2**, acetonitrile, diisopropylethyl amine, reflux; e) concentrated hydrochloric acid, reflux; f) $R_1\text{CHO}$, acetic acid, sodium methoxide, methanol, rt, then sodium cyanoborohydride. (R_1 , R_2 , R_3 , and R_4 are as defined above.)

Methylation of 2,4-dihydroxyquinoline (**1**) with dimethylsulfate, followed by treatment with trifluoroacetic anhydride furnished intermediate **2**, as outlined in Scheme 1 (see PCT application PCT/EP99/02648). Mono-protection of 2-phenyl-propane-1,3-diamine (Weinhardt et al. *J. Med. Chem.*, **1985**, 28, 694) afforded amine **3**. Coupling of **2** with amine **3** was accomplished in acetonitrile at reflux to give urethane **4**. Removal of the *tert*-butoxycarbonyl protecting group and simultaneous conversion of the quinoline to the quinolone with concentrated hydrochloric acid at reflux, followed by reductive alkylation of the resultant amines with various aldehydes provided the target compounds **5**.

Alternatively, **2** could be coupled with various aminopropyl amides as outlined in Scheme 2. Reduction of the amide carbonyl with borane-tetrahydrofuran followed by conversion of the quinoline to the quinolone under acidic conditions furnished amines **11**.



Conditions: a) ammonia, rt; b) hydrogen, palladium on carbon, ethanol, hydrochloric acid; c) 2, acetonitrile, diisopropylethyl amine, reflux; d) borane in tetrahydrofuran, reflux; e) concentrated hydrochloric acid, reflux; f) R₁CHO, acetic acid, sodium methoxide, methanol, rt, then sodium cyanoborohydride. (R₁, R₂, R₃, and R₄ are as defined above.)

Conversion of 1-cyano-cyclohexanecarboxylic acid ethyl ester (Julia et al., *Bull. Soc. Chim. Fr.* **1969**, 2427) to the corresponding amide using ammonia gas followed by hydrogenation provided amide 7. Coupling of 2 with amide 7 was accomplished in acetonitrile at reflux to give urethane 8, followed by borane reduction to amine 9. Conversion of the quinoline to the quinolone with concentrated hydrochloric acid at reflux, followed by reductive alkylation of the resultant amines with various aldehydes provided the target compounds 11.

In order to use a compound of the Formula (I) or a pharmaceutically acceptable salt thereof for the treatment of humans and other mammals it is normally formulated in accordance with standard pharmaceutical practice as a pharmaceutical composition.

Compounds of Formula (I) and their pharmaceutically acceptable salts may be administered in a standard manner for the treatment of the indicated diseases, for example orally, parenterally, sub-lingually, transdermally, rectally, via inhalation or via buccal administration.

Compounds of Formula (I) and their pharmaceutically acceptable salts which are active when given orally can be formulated as syrups, tablets, capsules and lozenges. A syrup formulation will generally consist of a suspension or solution of the compound or salt in a

liquid carrier for example, ethanol, peanut oil, olive oil, glycerine or water with a flavoring or coloring agent. Where the composition is in the form of a tablet, any pharmaceutical carrier routinely used for preparing solid formulations may be used. Examples of such carriers include magnesium stearate, terra alba, talc, gelatin, agar, pectin, acacia, stearic acid, starch, lactose and sucrose. Where the composition is in the form of a capsule, any routine encapsulation is suitable, for example using the aforementioned carriers in a hard gelatin capsule shell. Where the composition is in the form of a soft gelatin shell capsule any pharmaceutical carrier routinely used for preparing dispersions or suspensions may be considered, for example aqueous gums, celluloses, silicates or oils and are incorporated in a soft gelatin capsule shell.

Typical parenteral compositions consist of a solution or suspension of the compound or salt in a sterile aqueous or non-aqueous carrier optionally containing a parenterally acceptable oil, for example polyethylene glycol, polyvinylpyrrolidone, lecithin, arachis oil, or sesame oil.

Typical compositions for inhalation are in the form of a solution, suspension or emulsion that may be administered as a dry powder or in the form of an aerosol using a conventional propellant such as dichlorodifluoromethane or trichlorofluoromethane.

A typical suppository formulation comprises a compound of Formula (1) or a pharmaceutically acceptable salt thereof which is active when administered in this way, with a binding and/or lubricating agent, for example polymeric glycols, gelatins, cocoa-butter or other low melting vegetable waxes or fats or their synthetic analogues.

Typical transdermal formulations comprise a conventional aqueous or non-aqueous vehicle, for example a cream, ointment, lotion or paste or are in the form of a medicated plaster, patch or membrane.

Preferably the composition is in unit dosage form, for example a tablet, capsule or metered aerosol dose, so that the patient may administer to themselves a single dose.

Each dosage unit for oral administration contains suitably from 0.1 mg to 500 mg/Kg, and preferably from 1 mg to 100 mg/Kg, and each dosage unit for parenteral administration contains suitably from 0.1 mg to 100 mg, of a compound of Formula (I) or a pharmaceutically acceptable salt thereof calculated as the free acid. Each dosage unit for intranasal administration contains suitably 1-400 mg and preferably 10 to 200 mg per person. A topical formulation contains suitably 0.01 to 1.0% of a compound of Formula (I).

The daily dosage regimen for oral administration is suitably about 0.01 mg/Kg to 40 mg/Kg, of a compound of Formula (I) or a pharmaceutically acceptable salt thereof calculated as the free acid. The daily dosage regimen for parenteral administration is suitably about 0.001

mg/Kg to 40 mg/Kg, of a compound of the Formula (I) or a pharmaceutically acceptable salt thereof calculated as the free acid. The daily dosage regimen for intranasal administration and oral inhalation is suitably about 10 to about 500 mg/person. The active ingredient may be administered from 1 to 6 times a day, sufficient to exhibit the desired activity.

5 These quinolones may be used for the treatment of congestive heart failure, stroke, ischemic heart disease (angina, myocardial ischemia), cardiac arrhythmia, hypertension (essential and pulmonary), COPD, restenosis, asthma, neurogenic inflammation and metabolic vasculopathies, addiction, schizophrenia, impulsivity, anxiety, stress, depression, neuromuscular function, and diabetes.

10 No unacceptable toxicological effects are expected when compounds of the invention are administered in accordance with the present invention.

 The biological activity of the compounds of Formula (I) are demonstrated by the following tests:

Radioligand binding:

15 HEK-293 cell membranes containing stable cloned human and rat GPR-14 (20 ug/assay) were incubated with 200 pM [¹²⁵I] h-U-II (200 Ci/mmol⁻¹ in the presence of increasing concentrations of test compounds in DMSO (0.1 nM to 10 uM), in a final incubation volume of 200 ul (20 mM Tris-HCl, 5 mM MgCl₂). Incubation was done for 30 minutes at room temperature followed by filtration GF/B filters with Brandel cell harvester. ¹²⁵I labeled

20 U-II binding was quantitated by gamma counting. Nonspecific binding was defined by ¹²⁵I U-II binding in the presence of 100 nM of unlabeled human U-II. Analysis of the data was performed by nonlinear least square fitting.

Ca²⁺-mobilization:

 A microtitre plate based Ca²⁺-mobilization FLIPR assay (Molecular Devices, Sunnyvale, CA)

25 was used for the functional identification of the ligand activating HEK-293 cells expressing (stable) recombinant GPR-14. The day following transfection, cells were plated in a poly-D-lysine coated 96 well black/clear plates. After 18-24 hours the media was aspirated and Fluo 3AM-loaded cells were exposed to various concentrations (10 nM to 30 uM) of test compounds followed by h-U-II. After initiation of the assay, fluorescence was read every second for one

30 minute and then every 3 seconds for the following one minute. The inhibitory concentration at 50% (IC₅₀) was calculated for various test compounds.

Inositol phosphates assays:

HEK-293-GPR14 cells in T150 flask were prelabeled overnight with 1 uCi myo-[³H] inositol per ml of inositol free Dulbecco's modified Eagle's medium. After labeling, the cells were washed twice with Dulbecco's phosphate-buffered saline (DPBS) and then incubated in DPBS containing 10 mM LiCl for 10 min at 37°C. The experiment was initiated by the addition of increasing concentrations of h-U-II (1 pM to 1 μM) in the absence and presence of three different concentrations (0.3, 1 and 10 μM) of test compounds and the incubation continued for an additional 5 min at 37°C after which the reaction was terminated by the addition of 10% (final concentration) trichloroacetic acid and centrifugation. The supernatants were neutralized with 100 μl of 1M Trizma base and the inositol phosphates were separated on AG 1-X8 columns (0.8 ml packed, 100-200 mesh) in formate phase. Inositol monophosphate was eluted with 8 ml of 200 mM ammonium formate. Combined inositol di and tris phosphate was eluted with 4 ml of 1M ammonium formate/ 0.1 M formic acid. Eluted fractions were counted in beta scintillation counter. Based on shift from the control curve K_B was calculated.

Activity for the compounds of this invention range from 8 nM to 1 μM.

The following examples are illustrative and are not limiting if the compounds of this invention.

EXAMPLE 1

Preparation of 2-{3-[(1-Benzyl-1*H*-indol-3-yl)methyl]-amino}-2-phenyl-propylamino}-1*H*-quinolin-4-one

a) 2-Hydroxy-4-methoxyquinoline

A slurry of 2,4-dihydroxyquinoline (20.7 g, 0.13 mol), potassium carbonate (35.5 g, 0.26 mol), and dimethyl sulfate (14.6 ml, 0.15 mol) in acetone (800 ml) was heated at reflux for 3 days. The reaction was cooled to ambient temperature then evaporated under reduced pressure. The residue was slurried in a system of water (1000 ml) and ethyl acetate (500 ml) for 1 hour. The solids were collected then rinsed with water (3x250 ml) and ethyl ether (3x250 ml). Vacuum dried over phosphorus pentoxide to give 2-hydroxy-4-methoxyquinoline (16.3 g, 72%) as a tan powder. $[M+H]^+$ 176, $M+CH_3CN=217$.

b) 1,1,1-Trifluoromethanesulfonic acid 4-methoxyquinolin-2-yl ester

A slurry of 2-hydroxy-4-methoxyquinoline (13.4 g, 76.6 mmol) in pyridine (75 ml) was slowly treated under argon with trifluoromethanesulfonic anhydride (15.5 ml, 91.2 mmol). The reaction was allowed to stir at ambient temperature. After 4 days, the reaction was evaporated under reduced pressure to an oil that was azeotroped from toluene (2x200 ml) to give the crude product as a brown solid. Flash chromatography on silica (1:1 ethyl acetate/hexanes as eluent) gave 1,1,1-trifluoromethanesulfonic acid 4-methoxyquinolin-2-yl ester (20.4 g, 87%) as a yellow oil that solidified on standing. $[M+H]^+$ 308, $M+CH_3CN=349$.

10 c) (3-Amino-2-phenyl-propyl)-carbamic acid tert-butyl ester

A solution of 2-phenyl-propane-1,3-diamine (2.20g, 14.7 mmol) in dry tetrahydrofuran (70 mL) was cooled to 0 °C and treated over 30 minutes with a solution of di-tert-butyl dicarbonate (0.33 eq, 4.88 mmol, 1.10g) in dry tetrahydrofuran (20 mL). The mixture was allowed to warm to room temperature, stirring overnight. The thick slurry was then concentrated to a white residue, taken into water, and extracted into ethyl acetate. The organic extracts were washed with brine (2x), dried over Na_2SO_4 , filtered, and concentrated to a colorless oil (1.16g, 95%). $[M+H]^+$ 251.

d) [3-(4-Methoxyquinolin-2-ylamino)-2-phenyl-propyl]carbamic acid tert-butyl ester

20 A solution of 1,1,1-trifluoromethanesulfonic acid 4-methoxyquinolin-2-yl ester (1.08 g, 3.52 mmol), (3-amino-2-phenyl-propyl)-carbamic acid tert-butyl ester (1.0 eq, 3.52 mmol, 0.88g), and diisopropylethylamine (2.5 eq, 8.80 mmol, 1.53 mL) in anhydrous acetonitrile (10 ml) was heated at reflux for 3 days. The solution was cooled to ambient temperature then evaporated under reduced pressure to a yellow residue. It was taken into water (35 ml) then extracted into ethyl acetate. The extracts were dried (sodium sulfate) then concentrated to an orange oil. Column chromatography on silica (gradient from 1:3 ethyl acetate/hexanes to 1:2 ethyl acetate/hexanes) gave the product (0.54 g, 38%) as a white foamy solid. $[M+H]^+$ 408.

e) 2-(3-Amino-2-phenyl-propylamino)-1*H*-quinolin-4-one dihydrochloride

30 A solution of [3-(4-methoxyquinolin-2-ylamino)-2-phenyl-propyl]carbamic acid tert-butyl ester (0.21 g, 0.51 mmol) in concentrated hydrochloric acid (25 mL) was heated to reflux for 24 hours. It was evaporated under reduced pressure and azeotroped from toluene to give the product which was immediately carried on to the next step.

f) 2-{3-[(1-Benzyl-1*H*-indol-3-ylmethyl)-amino]-2-phenyl-propylamino}-1*H*-quinolin-4-one

A solution of 2-(3-amino-2-phenyl-propylamino)-1*H*-quinolin-4-one dihydrochloride (step 1e, crude) in methanol (50 ml) was treated with glacial acetic acid (20 drops) and sodium methoxide (95%, 55 mg, 1.02 mmol) followed by a solution of 1-benzyl-3-indole
5 carboxaldehyde (120 mg, 0.51 mmol) in methanol (5.0 ml). The reaction stirred at ambient temperature for 24 hours then was treated with a solution of sodium cyanoborohydride (64 mg, 1.02 mmol) in methanol (5.0 ml). The reaction stirred at ambient temperature for 24 hours. The solution was evaporated under reduced pressure to a residue that was taken into a mixture of saturated aqueous sodium chloride (30 ml) and 10% sodium hydroxide solution (30 ml). It
10 was extracted in ethyl acetate and the extracts were dried (sodium sulfate) then concentrated to a white residue. Column chromatography on silica (95/5 dichloromethane/methanolic ammonia) gave the title compound (124 mg, 47%) as a white solid. $[M+H]^+$ 513.

EXAMPLE 2

15 Preparation of 2-[(1-{[(1-Benzyl-1*H*-indol-3-ylmethyl)-amino]-methyl}-cyclohexylmethyl)-amino]-1*H*-quinolin-4-one

a) 1-Cyano-cyclohexanecarboxylic acid amide

1-Cyano-cyclohexanecarboxylic acid ethyl ester (11.4g, 63.0 mmol) was placed into a glass pressure vessel and cooled to -78 °C. It was charged with ammonia via needle until the
20 total volume had doubled. The vessel was sealed and allowed to stir at room temperature for 20 hours. The solvent was evaporated and the resulting slurry triturated with ethyl acetate. The solids were collected by filtration and then filtered through a silica funnel (50g silica), washing with ethyl acetate. The filtrate was concentrated to give the product (2.51g, 26%) as a white solid. $[M+H]^+$ 153.

25

b) 1-Aminomethyl-cyclohexanecarboxylic acid amide hydrochloride

A solution of 1-cyano-cyclohexanecarboxylic acid amide (2.34g, 20.0 mmol) in ethanol (50 mL) was treated with concentrated HCl (3 mL) and 10% degussa palladium on carbon (0.50g). The mixture was subjected to hydrogenation conditions (50 psi) for 24 hours, then
30 filtered through Celite. The filtrate was concentrated, then azeotroped with methanol to give a viscous oil. The oil was then resubjected to the above hydrogenation conditions for an additional 20 hours. It was filtered and concentrated as above to give the product (3.85g, 100%) as a white solid. $[M+H]^+$ 157.

c) 1-[(4-Methoxy-quinolin-2-yl-amino)-methyl]-cyclohexanecarboxylic acid amide

Following the procedure of Example 1d, except substituting 1-aminomethyl-cyclohexanecarboxylic acid amide hydrochloride for (3-amino-2-phenyl-propyl)-carbamic acid tert-butyl ester, the product (2.11g, 59%) was obtained as a white solid. $[M+H]^+$ 314.

5

d) 1-(Aminomethyl-cyclohexylmethyl)-(4-methoxy-quinolin-2-yl)-amine dihydrochloride

A solution of 1-[(4-methoxy-quinolin-2-yl-amino)-methyl]-cyclohexanecarboxylic acid amide (1.81g, 5.79 mmol) in anhydrous tetrahydrofuran (20 mL) was heated at reflux for 24 hours. It was cooled to room temperature and treated slowly with concentrated hydrochloric acid (1.5 mL). The mixture stirred for an additional hour, then was concentrated to a wet residue. This was taken up into 10% sodium hydroxide (35 mL) and brine (35 mL) and extracted into ethyl acetate. The organic extracts were washed with brine, dried over Na_2SO_4 , filtered, and concentrated. The resulting yellow oil was taken into methylene chloride (20 mL) and treated with 4N HCl in dioxane (3 mL). It was concentrated to afford the product (2.10g, 97%) as a yellow solid. $[M+H]^+$ 300.

10
15e) 2-[(1-Aminomethyl-cyclohexylmethyl)-amino]-1*H*-quinolin-4-one dihydrochloride

1-(Aminomethyl-cyclohexylmethyl)-(4-methoxy-quinolin-2-yl)-amine dihydrochloride (1.19g, 3.20 mmol) was taken up in concentrated hydrochloric acid (35 mL) and heated to reflux for 20 hours. It was cooled to room temperature and concentrated. The wet residue was azeotroped from toluene to give the product (1.15g, 100%) as a tan powder. $[M+H]^+$ 286.

20

f) 2-[(1-[(1-Benzyl-1*H*-indol-3-ylmethyl)-amino]-methyl)-cyclohexylmethyl)-amino]-1*H*-quinolin-4-one

25

Following the procedure of Example 1f, except substituting 2-[(1-aminomethyl-cyclohexylmethyl)-amino]-1*H*-quinolin-4-one dihydrochloride for 2-(3-amino-2-phenyl-propylamino)-1*H*-quinolin-4-one, the title compound (0.098g, 25%) was obtained as a colorless oil that solidified upon standing. $[M+H]^+$ 505.

30

EXAMPLE 3

Formulations for pharmaceutical use incorporating compounds of the present invention can be prepared in various forms and with numerous excipients. Examples of such formulations are given below.

Inhalant Formulation

A compound of Formula I, (1 mg to 100 mg) is aerosolized from a metered dose inhaler to deliver the desired amount of drug per use.

| | | |
|----|---|-------------------|
| 5 | <u>Tablets/Ingredients</u> | <u>Per Tablet</u> |
| | 1.Active ingredient (Cpd of Form. I) | 40 mg |
| | 2.Corn Starch | 20 mg |
| | 3.Alginic acid | 20 mg |
| 10 | 4.Sodium Alginate | 20 mg |
| | 5.Mg stearate | <u>1.3 mg</u> |
| | | 2.3 mg |

Procedure for tablets:

- 15 Step 1: Blend ingredients No. 1, No. 2, No. 3 and No. 4 in a suitable mixer/blender.
 Step 2: Add sufficient water portion-wise to the blend from Step 1 with careful mixing after each addition. Such additions of water and mixing until the mass is of a consistency to permit its conversion to wet granules.
 Step 3: The wet mass is converted to granules by passing it through an oscillating granulator
 20 using a No. 8 mesh (2.38 mm) screen.
 Step 4: The wet granules are then dried in an oven at 140°F (60°C) until dry.
 Step 5: The dry granules are lubricated with ingredient No. 5.
 Step 6: The lubricated granules are compressed on a suitable tablet press.


25 Parenteral Formulation

A pharmaceutical composition for parenteral administration is prepared by dissolving an appropriate amount of a compound of formula I in polyethylene glycol with heating. This solution is then diluted with water for injections Ph Eur. (to 100 ml). The solution is then sterilized by filtration through a 0.22 micron membrane filter and sealed in sterile containers.

- 30 The above specification and Examples fully disclose how to make and use the compounds of the present invention. However, the present invention is not limited to the particular embodiments described hereinabove, but includes all modifications thereof within the scope of the following claims. The various references to journals, patents and other publications which are cited herein comprise the state of the art and are incorporated herein by
 35 reference as though fully set forth.

What is claimed is:

1. A compound of Formula (I)



(I)

wherein:

R₁ is phenyl, thienyl, benzothienyl, benzhydryl, xanthenyl, naphthyl, or indolyl, all of which may be substituted or unsubstituted by one or two substituents selected from: halogens,

10 -CN, CH₃CO-, (C₁₋₆)alkyl, mono to perfluoro(C₁₋₃)alkyl, (C₂₋₆)alkenyl, (C₁₋₆)alkoxy, (C₅₋₁₀)aryloxy, phenylC₍₁₋₆₎alkoxy, -OH, -NH₂, mono- or di-(C₁₋₆)alkylamino, -NO₂, -CO₂H, -CO₂(C₁₋₆)alkyl, -S(C₁₋₆)alkyl, -SO₂(C₁₋₆)alkyl, H₂NSO₂-, -CONH₂, -SO₂(C₅₋₁₀)aryl, or -CO₂N{(C₁₋₆)alkyl}₂;

R₂ is hydrogen or Me;

15 R₃ is hydrogen, I, F, Br, Cl, C₁₋₆alkyl, C₁₋₆alkoxy, -OH, or -CN;

X is $-\text{CH}(\text{R}_4)-$;

R₄ is hydrogen, CO, C₁₋₆ alkyl, or phenyl;

Y is $-\text{CH}_2\text{C}(\text{R}_5)(\text{R}_6)\text{CH}_2-$;

R₅ is hydrogen, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, benzyl, or phenyl, wherein the benzyl or phenyl group may be substituted or unsubstituted by one or two carboxy, cyano, OH or halo groups;

R₆ is benzyl, C₃₋₆ cycloalkyl, or phenyl, wherein the benzyl or phenyl group may be substituted or unsubstituted by one or two carboxy, cyano, OH or halo groups;

or R₅ and R₆ together with the carbon they are attached to may form a C₃₋₇ cycloalkyl group;

25 or a pharmaceutically acceptable salt thereof.

2. A compound according to claim 1 wherein R₁ is substituted phenyl, thienyl, benzothienyl, benzhydryl, or indolyl; R₂ is hydrogen; R₃ is hydrogen, halo, or alkyl;

X is CH₂; and Y is CH₂CR₅R₆CH₂, where R₅, and R₆ are.

3. A compound according to claim 2 wherein R₁ is 1-benzyl-3-indolyl, 4,6-dichloro-2-indolyl, 3-trifluoromethylthiophenyl, 2-fluoro-5-trifluoromethylphenyl, 4,6-dichloro-3-methyl-
5 2-indolyl, 6-methoxy-4-trifluoromethyl-2-indolyl, 3,4-dichlorophenyl, 3,5-dibromophenyl; R₂ is hydrogen; R₃ is hydrogen, Cl, or Me; X is CH₂, and Y is CH₂CR₅R₆CH₂, wherein R₅, and R₆ are
4. A compound according to claim 1 wherein the compound is selected from:
10 2-{3-[(1-Benzyl-1*H*-indol-3-ylmethyl)-amino]-2-phenyl-propylamino}-1*H*-quinolin-4-one; and
2-[(1-{[(1-Benzyl-1*H*-indol-3-ylmethyl)-amino]-methyl}-cyclohexylmethyl)-amino]-1*H*-quinolin-4-one.
5. A pharmaceutical composition comprising a compound of formula (I) of claim 1
15 and a pharmaceutically acceptable carrier or excipient.
6. A method of treating conditions associated with Urotensin-II imbalance by antagonizing the Urotensin-II receptor which comprises administering to a patient in need thereof, a compound of Formula I of claim 1.
20
7. A method according to Claim 6 wherein the disease is congestive heart failure, stroke, ischemic heart disease, angina, myocardial ischemia, cardiac arrhythmias, essential hypertension, pulmonary hypertension, COPD, restenosis, asthma, neurogenic inflammation metabolic vasculopathies, addiction, schizophrenia, impulsivity, anxiety, stress, depression,
25 neuromuscular function, or diabetes.